# NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer

> **NCT02030561** · PHASE1,PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 29 (estimated)

## Conditions studied

- Breast Cancer
- Gastric Cancer

## Interventions

- **DRUG:** Trastuzumab + NK cells

## Key facts

- **NCT ID:** NCT02030561
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2017-08
- **Final completion:** 2018-08
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2016-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02030561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02030561, "NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02030561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*